The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASCO 2019 | Is immunotherapy toxicity associated with improved overall survival among older adults with MM?

Jun 3, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Ashley Elizabeth Rosko, Ohio State University Wexner Medical Center, discusses how immunotherapy toxicity is associated with improved overall survival among older adults with multiple myeloma. Dr. Rosko discusses how immunotherapy is becoming the standard of care for patients who are both newly diagnosed and in the relapsed setting; and how identifying toxicities that are unique for immunotherapy are particularly relevant for older adults. However, Dr. Rosko emphasizes that when utilizing these therapies which are both safe and effective, understanding the long term consequences need to be reevaluated.

Is immunotherapy toxicity associated with improved overall survival among older adults with MM?